XML 54 R30.htm IDEA: XBRL DOCUMENT

Business Segment Data (Tables)

9 Months Ended

Sep. 30, 2011

Net Revenue And Operating Income (Loss) By Segment


	Three Months Ended September 30,				Nine Months Ended September 30,
	2010		2011		2010			2011
Net revenue:
Clinical Development Services	$	260,345	$	292,025	$	765,075		$	863,230
Laboratory Services		79,045		90,848		231,921			252,007
Discovery Sciences		—		—		8,010			—
Reimbursed revenue		25,985		32,522		77,054			91,063

Total	$	365,375	$	415,395	$	1,082,060		$	1,206,300


Operating income (loss):
Clinical Development Services	$	43,681	$	53,771	$	101,830		$	148,748
Laboratory Services		13,154		11,648		34,631			26,266
Discovery Sciences		—		—		(11,860	)		—

Total	$	56,835	$	65,419	$	124,601		$	175,014

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details